Asset
ALBIGLUTIDE
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Revenue
No revenue reported in loaded filings.
Clinical trials (26)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01733758 | phase3 | completed | 2013-02-01 | 2014-06-01 | GlaxoSmithKline | A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) |
| NCT01357850 | phase2 | completed | 2010-09-15 | 2012-09-18 | GlaxoSmithKline | A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure |
| NCT02802514 | phase4 | terminated | 2016-09-20 | 2017-08-10 | GlaxoSmithKline | A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects |
| NCT02496221 | phase4 | completed | 2015-06-11 | 2015-10-13 | GlaxoSmithKline | A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects |
| NCT01098539 | phase3 | completed | 2010-05-01 | 2012-11-01 | GlaxoSmithKline | A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125431 | BLA | GlaxoSmithKline LLC |
Marketed products (2)
- TANZEUM
- Tanzeum